STAT3: A Target to Enhance Antitumor Immune Response
Open accessThe DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Abstract
Signal transducer and activator of transcription 3 (Stat3) has emerged as a critical regulator for tumor-associated inflammation. Activation of Stat3 negatively regulates the Th1-type immune response and promotes expansion of myeloid-derived suppressor cells (MDSCs) and regulatory T-cell functions in the tumor microenvironment. Mounting evidence suggests that Stat3 and related pathways may serve as a target for changing the tumor immunologic microenvironment to benefit cancer immunotherapies. Many recent studies support the use of certain tyrosine kinase inhibitors, through inhibition of Stat3, in decreasing immunosuppression in the tumor microenvironment. Other potential therapeutic avenues include the use of targeted delivery of Stat3 siRNA into immune cells. Here, we describe the role of Stat3 in regulating the immunologic properties of tumors as a background for Stat3-based therapeutic interventions.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sorafenib in advanced hepatocellular carcinoma
Llovet, J. M., Ricci, S., Mazzaferro, V., Hilgard, P., Gane, E., Blanc, J.-F., de Oliveira, A. C., Santoro, A., Raoul, J.-L., Forner, A., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0708857 · Cited by 13,097
Myeloid-derived-suppressor cells as regulators of the immune system
Gabrilovich, D. I., & Nagaraj, S. (2009) · Nature Reviews Immunology · doi:10.1038/nri2506 · Cited by 6,753
Erlotinib in Previously Treated Non–Small-Cell Lung Cancer
Shepherd, F. A., Rodrigues Pereira, J., Ciuleanu, T., Tan, E. H., Hirsh, V., Thongprasert, S., Campos, D., Maoleekoonpiroj, S., Smylie, M., Martins, R., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050753 · Cited by 5,419 · cited 1×
“Targeting RTKs can be a clinically effective strategy across a wide variety of malignancies, including lung cancer, hepatocellular carcinoma (HCC) and mRCC (Llovet et al. 2008; Motzer et al. 2009; Shepherd et al. 2005).”
BackgroundCancer immunoediting: from immunosurveillance to tumor escape
Dunn, G. P., Bruce, A. T., Ikeda, H., Old, L. J., & Schreiber, R. D. (2002) · Nature Immunology · doi:10.1038/ni1102-991 · Cited by 5,393 · cited 2×
“1 Introduction The ability of tumors to evade immune surveillance plays a central role in tumor progression (Dunn et al. 2002; Yu et al. 2007).”
BackgroundCuriel, T. J., Coukos, G., Zou, L., Alvarez, X., Cheng, P., Mottram, P., Evdemon-Hogan, M., Conejo-Garcia, J. R., Zhang, L., Burow, M., et al. (2004) · Nature Medicine · doi:10.1038/nm1093 · Cited by 5,151 · cited 2×
“2.4 Role in Regulatory T-Cells Regulatory T-cells (Tregs) are critical in the induction of T-cell tolerance to tumor antigens by suppressing immune responses mediated by CD8+ T cells (Curiel et al. 2004; Liyanage et al. 2002; Viguier et al. 2004; Yang et al. 2006).”
BackgroundInfluentialSTATs in cancer inflammation and immunity: a leading role for STAT3
Yu, H., Pardoll, D., & Jove, R. (2009) · Nature reviews. Cancer · doi:10.1038/nrc2734 · Cited by 4,383 · cited 15×
“2.2 Relevant Immunologic Signaling Pathways Tumors produce various factors that in turn activate Stat3 by forming feed-forward loops with signaling pathways (Yu et al. 2007, 2009).”
BackgroundResultInfluentialSelf-citationIL-23 drives a pathogenic T cell population that induces autoimmune inflammation
Langrish, C. L., Chen, Y., Blumenschein, W. M., Mattson, J., Basham, B., Sedgwick, J. D., McClanahan, T., Kastelein, R. A., & Cua, D. J. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20041257 · Cited by 4,099 · cited 5×
“Unlike IL-12, IL-23 does not promote IFN-g-producing Th1 cells, but is one of the essential factors required for the expansion of a pathogenic memory T cell population, which is characterized by the production of IL-17, IL-6, and tumor necrosis factor (TNF) (Langrish et al. 2005).”
BackgroundInfluentialDruker, B. J., Sawyers, C. L., Kantarjian, H., Resta, D. J., Reese, S. F., Ford, J. M., Capdeville, R., & Talpaz, M. (2001) · New England Journal of Medicine · doi:10.1056/nejm200104053441402 · Cited by 2,713
The STATs of cancer — new molecular targets come of age
Yu, H., & Jove, R. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1275 · Cited by 2,278 · cited 2×
“…that ablation of Stat3 in tumor cells or tumor-associated immune cells decreases tumor progression Kortylewski et al. (2005), Wang et al. (2004), Yu and Jove (2004), and Yu et al. (2007, 2009) JAK inhibitors Use of these agents (i.e., AG490, WP1066, AZD1480) decreases Stat3 activation and…”
BackgroundSelf-citationGrivennikov, S., Karin, E., Terzic, J., Mucida, D., Yu, G.-Y., Vallabhapurapu, S., Scheller, J., Rose-John, S., Cheroutre, H., Eckmann, L., et al. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.01.001 · Cited by 2,155
Wu, S., Rhee, K.-J., Albesiano, E., Rabizadeh, S., Wu, X., Yen, H.-R., Huso, D. L., Brancati, F. L., Wick, E., McAllister, F., et al. (2009) · Nature Medicine · doi:10.1038/nm.2015 · Cited by 1,812
Takeda, K., Clausen, B. E., Kaisho, T., Tsujimura, T., Terada, N., Förster, I., & Akira, S. (1999) · Immunity · doi:10.1016/s1074-7613(00)80005-9 · Cited by 1,220
Impaired TH17 cell differentiation in subjects with autosomal dominant hyper-IgE syndrome
Milner, J. D., Brenchley, J. M., Laurence, A., Freeman, A. F., Hill, B. J., Elias, K. M., Kanno, Y., Spalding, C., Elloumi, H. Z., Paulson, M. L., et al. (2008) · Nature · doi:10.1038/nature06764 · Cited by 1,157
McGeachy, M. J., Chen, Y., Tato, C. M., Laurence, A., Joyce-Shaikh, B., Blumenschein, W. M., McClanahan, T. K., O'Shea, J. J., & Cua, D. J. (2009) · Nature Immunology · doi:10.1038/ni.1698 · Cited by 1,074 · cited 2×
“2002) and is required for the terminal differentiation of Th17 cell into effector cells in a Stat3dependent fashion (McGeachy et al. 2009).”
BackgroundIL-23 promotes tumour incidence and growth
Langowski, J. L., Zhang, X., Wu, L., Mattson, J. D., Chen, T., Smith, K., Basham, B., McClanahan, T., Kastelein, R. A., & Oft, M. (2006) · Nature · doi:10.1038/nature04808 · Cited by 1,018 · cited 2×
“In contrast to its role in promoting inflammatory responses, IL-23 has been implicated in tumor-mediated immunosuppression (Kortylewski et al. 2009c; Langowski et al. 2006).”
BackgroundCD4 + Regulatory T Cells Control T H 17 Responses in a Stat3-Dependent Manner
Chaudhry, A., Rudra, D., Treuting, P., Samstein, R. M., Liang, Y., Kas, A., & Rudensky, A. Y. (2009) · Science · doi:10.1126/science.1172702 · Cited by 1,000 · cited 2×
“Stat3 binds to the promoter of Foxp3, although to a lesser extent compared to Stat5 (Yao et al. 2007; Zorn et al. 2006), and physically interacts with Foxp3 protein (Chaudhry et al. 2009).”
BackgroundBollrath, J., Phesse, T. J., von Burstin, V. A., Putoczki, T., Bennecke, M., Bateman, T., Nebelsiek, T., Lundgren-May, T., Canli, Ö., Schwitalla, S., et al. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.01.002 · Cited by 946 · cited 16×
“Demonstrating cross-talk amongst these pathways, IL-6 is shown to upregulate production of IL-10 in both colon cancer cell lines and T cells through Stat3 activation (Herbeuval et al. 2004; Stumhofer et al. 2007).”
BackgroundInfluentialSinha, P., Clements, V. K., Bunt, S. K., Albelda, S. M., & Ostrand-Rosenberg, S. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.179.2.977 · Cited by 847
Hoechst, B., Ormandy, L. A., Ballmaier, M., Lehner, F., Krüger, C., Manns, M. P., Greten, T. F., & Korangy, F. (2008) · Gastroenterology · doi:10.1053/j.gastro.2008.03.020 · Cited by 793 · cited 2×
“Of interest, co-culturing MDSCs with T cells induces the Foxp3 Treg phenotype in both mouse and human tumor models, leading to tumor-induced T cell tolerance (Hoechst et al. 2008; Serafini et al. 2008).”
BackgroundPersistently Activated Stat3 Maintains Constitutive NF-κB Activity in Tumors
Lee, H., Herrmann, A., Deng, J.-H., Kujawski, M., Niu, G., Li, Z., Forman, S., Jove, R., Pardoll, D. M., & Yu, H. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.02.015 · Cited by 683 · cited 5×
“Persistent Stat3 activation can be propagated from tumor cells to diverse immune cells through factors such as IL-6, IL-10, and VEGF (Kortylewski et al. 2005; Kujawski et al. 2008; Lee et al. 2009; Sumimoto et al. 2006; Wang et al. 2004; Yu et al. 2007, 2009).”
BackgroundInfluentialSelf-citationDeficiency of Th17 cells in hyper IgE syndrome due to mutations in STAT3
Ma, C. S., Chew, G. Y. J., Simpson, N., Priyadarshi, A., Wong, M., Grimbacher, B., Fulcher, D. A., Tangye, S. G., & Cook, M. C. (2008) · The Journal of Experimental Medicine · doi:10.1084/jem.20080218 · Cited by 652
Ozao-Choy, J., Ma, G., Kao, J., Wang, G. X., Meseck, M., Sung, M., Schwartz, M., Divino, C. M., Pan, P.-Y., & Chen, S.-H. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-4709 · Cited by 538 · cited 6×
“While treatment with sunitinib results in inhibition of Treg mediators such as IL-10, TGF-b, and Foxp3, it also elevates Th1 cytokine and IFNg in murine models ( Ozao-Choy et al. 2009 ).”
BackgroundInfluentialIL-6 regulates in vivo dendritic cell differentiation through STAT3 activation
Park, S.-J., Nakagawa, T., Kitamura, H., Atsumi, T., Kamon, H., Sawa, S.-I., Kamimura, D., Ueda, N., Iwakura, Y., Ishihara, K., et al. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.173.6.3844 · Cited by 519 · cited 1×
“Specifically, release of IL-10, VEGF, and IL-6 prevents immature dendritic cells (DCs) from maturing into antigen-presenting cells (Gabrilovich 2004; Gabrilovich et al. 1996; Ohm et al. 2003; Park et al. 2004).”
BackgroundHyperactivation of STAT3 is involved in abnormal differentiation of dendritic cells in cancer
Nefedova, Y., Huang, M., Kusmartsev, S., Bhattacharya, R., Cheng, P., Salup, R., Jove, R., & Gabrilovich, D. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.172.1.464 · Cited by 464 · cited 1×
“Exposure of myeloid cells to tumor cell conditioned medium upregulates Stat3 activity and triggers MDSC expansion (Nefedova et al. 2004).”
BackgroundWelte, T., Zhang, S. S. M., Wang, T., Zhang, Z., Hesslein, D. G. T., Yin, Z., Kano, A., Iwamoto, Y., Li, E., Craft, J. E., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0237137100 · Cited by 381 · cited 10×
“Deletion of Stat3 facilitates activation of NF-κB (Welte et al. 2003) and Stat1 (Takeda et al. 1999), leading to increased production of Th1 type immune mediators required for anti-tumor immunity (Kortylewski et al. 2009c; Yu et al. 2009).”
BackgroundInfluentialRahaman, S. O., Harbor, P. C., Chernova, O., Barnett, G. H., Vogelbaum, M. A., & Haque, S. J. (2002) · Oncogene · doi:10.1038/sj.onc.1206047 · Cited by 377 · cited 1×
“The prototype Jak inhibitor, AG490, prevents Stat3 phosphorylation and activation of its downstream pro-survival genes (Rahaman et al. 2002).”
BackgroundThe tumor-promoting actions of TNF-α involve TNFR1 and IL-17 in ovarian cancer in mice and humans
Charles, K. A., Kulbe, H., Soper, R., Escorcio-Correia, M., Lawrence, T., Schultheis, A., Chakravarty, P., Thompson, R. G., Kollias, G., Smyth, J. F., et al. (2009) · Journal of Clinical Investigation · doi:10.1172/jci39065 · Cited by 338
Bewry, N. N., Nair, R. R., Emmons, M. F., Boulware, D., Pinilla-Ibarz, J., & Hazlehurst, L. A. (2008) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-0314 · Cited by 150
Kortylewski, M., Kujawski, M., Herrmann, A., Yang, C., Wang, L., Liu, Y., Salcedo, R., & Yu, H. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-3031 · Cited by 122 · cited 8×
“Furthermore, conjugation of CpG to siRNA targeting Stat3 activates various populations of immune cells including DCs and macrophages and ultimately induces robust anti-tumor immune responses (Kortylewski et al. 2009b).”
BackgroundInfluentialSelf-citation
Cited by
Targeting the IL-6/JAK/STAT3 signalling axis in cancer
Johnson, D. E., O'Keefe, R. A., & Grandis, J. R. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2018.8 · Cited by 3,110
Combining immunotherapy and targeted therapies in cancer treatment
Vanneman, M., & Dranoff, G. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3237 · Cited by 1,586
Clara, J. A., Monge, C., Yang, Y., & Takebe, N. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0293-2 · Cited by 752
A Potent and Selective Small-Molecule Degrader of STAT3 Achieves Complete Tumor Regression In Vivo
Bai, L., Zhou, H., Xu, R., Zhao, Y., Chinnaswamy, K., McEachern, D., Chen, J., Yang, C.-Y., Liu, Z., Wang, M., et al. (2019) · Cancer Cell · doi:10.1016/j.ccell.2019.10.002 · Cited by 652
The potential and controversy of targeting STAT family members in cancer
Verhoeven, Y., Tilborghs, S., Jacobs, J., De Waele, J., Quatannens, D., Deben, C., Prenen, H., Pauwels, P., Trinh, X. B., Wouters, A., et al. (2020) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.10.002 · Cited by 409
Metadata
- Authors
- Lee, H., Pal, S. K., Reckamp, K., Figlin, R. A., & Yu, H.
- Venue
- Current Topics in Microbiology and Immunology
- Publisher
- Springer Berlin Heidelberg
- Published
- 2010
- Volume
- 344
- Pages
- 41-59
- ISSN
- 0070-217X (ISSN-L)
- OpenAlex
- W1505531771
- Cited by
- 134
- References
- 29
- FWCI
- 11.10
- Type
- book chapter
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.